A possible new vaccine, aimed to protect against the COVID-19 virus, will be in production soon, WDIV reported.
The developers, Sanofi and GlaxoSmithKline, said Thursday, May 27 while starting a large trial enrolling 35,000 adult volunteers in the United States, Asia, Africa and Latin America, per the article.
The volunteer study will use vaccine candidate formulas against the original coronavirus that spread from Wuhan, China, and against the variant first seen in South Africa, the pharmaceutical firms said in the article.
If all goes well, regulators could approve the vaccine for use starting in the fall, the drugmakers were quoted saying.
“Manufacturing will begin in the coming weeks to enable rapid access to the vaccine, should it be approved,” they said in the article.
Thomas Triomphe, who leads vaccine research and development at Sanofi Pasteur, said in a quote: “We are encouraged to see first vaccinations starting to take place in such an important, pivotal Phase 3 study.”
Read the full story here.